Effects of 12 Months Consumption of 100 g Dried Plum (Prunes) on Bone Biomarkers, Density, and Strength in Men

Author(s):  
Shirin Hooshmand ◽  
Danielle Gaffen ◽  
Ashley Eisner ◽  
Jonnatan Fajardo ◽  
Mark Payton ◽  
...  
Keyword(s):  
Nutrients ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 1250
Author(s):  
Sarah J. Wherry ◽  
Ryan M. Miller ◽  
Sarah H. Jeong ◽  
Kristen M. Beavers

Despite the adverse metabolic and functional consequences of obesity, caloric restriction- (CR) induced weight loss is often contra-indicated in older adults with obesity due to the accompanying loss of areal bone mineral density (aBMD) and subsequent increased risk of fracture. Several studies show a positive effect of exercise on aBMD among weight-stable older adults; however, data on the ability of exercise to mitigate bone loss secondary to CR are surprisingly equivocal. The purpose of this review is to provide a focused update of the randomized controlled trial literature assessing the efficacy of exercise as a countermeasure to CR-induced bone loss among older adults. Secondarily, we present data demonstrating the occurrence of exercise-induced changes in bone biomarkers, offering insight into why exercise is not more effective than observed in mitigating CR-induced bone loss.


2021 ◽  
Author(s):  
Naheed Aryaeian ◽  
Fatemehsadat Amiri ◽  
Seyedeh Tayebeh Rahideh ◽  
Jamileh Abolghasemi ◽  
Shima Jazayeri ◽  
...  

2011 ◽  
Vol 90 (6) ◽  
pp. 747-751 ◽  
Author(s):  
J.B. Payne ◽  
J.A. Stoner ◽  
H.-M. Lee ◽  
P.V. Nummikoski ◽  
R.A. Reinhardt ◽  
...  

2021 ◽  
Vol 22 (23) ◽  
pp. 12651
Author(s):  
Akari Nakamura-Utsunomiya

The accumulation of glycosaminoglycans (GAGs) in bone and cartilage leads to progressive damage in cartilage that, in turn, reduces bone growth by the destruction of the growth plate, incomplete ossification, and growth imbalance. The mechanisms of pathophysiology related to bone metabolism in mucopolysaccharidoses (MPS) include impaired chondrocyte function and the failure of endochondral ossification, which leads to the release of inflammatory cytokines via the activation of Toll-like receptors by GAGs. Although improvements in the daily living of patients with MPS have been achieved with enzyme replacement, treatment for the bone disorder is limited. There is an increasing need to identify biomarkers related to bone and cartilage to evaluate the progressive status and to monitor the treatment of MPS. Recently, new analysis methods, such as proteomic analysis, have identified new biomarkers in MPS. This review summarizes advances in clinical bone metabolism and bone biomarkers.


2010 ◽  
Vol 24 (S1) ◽  
Author(s):  
Maria Esther Rio ◽  
Hernán C Dupraz ◽  
Liliana B Zago ◽  
Norma Piazza ◽  
Susana N Zeni

2020 ◽  
Vol 4 (9) ◽  
Author(s):  
Mikkel B Christensen ◽  
Asger B Lund ◽  
Niklas R Jørgensen ◽  
Jens J Holst ◽  
Tina Vilsbøll ◽  
...  

Abstract Context In healthy individuals, glucose-dependent insulinotropic polypeptide (GIP) enhances insulin secretion and reduces bone resorption by up to 25% estimated by absolute placebo-corrected changes in carboxy-terminal type 1 collagen crosslinks (CTX) during GIP and glucose administration. In patients with type 2 diabetes (T2D), GIP’s insulinotropic effect is impaired and effects on bone may be reduced. Objective To investigate GIP’s effect on bone biomarkers in patients with T2D. Design Randomized, double-blinded, crossover study investigating 6 interventions. Patients Twelve male patients with T2D. Interventions A primed continuous 90-minute GIP infusion (2 pmol/kg/min) or matching placebo (saline) administered at 3 plasma glucose (PG) levels (i.e., paired days with “insulin-induced hypoglycemia” (PG lowered to 3 mmol/L), “fasting hyperglycemia” (mean PG ~8 mmol/L), or “aggravated hyperglycemia” (mean PG ~12 mmol/L). Main Outcome Measures Bone biomarkers: CTX, procollagen type 1 N-terminal propeptide (P1NP) and PTH. Results On days with insulin-induced hypoglycemia, CTX was suppressed by up to 40 ± 15% during GIP administration compared with 12 ± 11% during placebo infusion (P < 0.0001). On days with fasting hyperglycemia, CTX was suppressed by up to 36 ± 15% during GIP administration, compared with 0 ± 9% during placebo infusion (P < 0.0001). On days with aggravated hyperglycemia, CTX was suppressed by up to 47 ± 23% during GIP administration compared with 10 ± 9% during placebo infusion (P = 0.0005). At all glycemic levels, P1NP and PTH concentrations were similar between paired days after 90 minutes. Conclusions Short-term GIP infusions reduce bone resorption by more than one-third (estimated by absolute placebo-corrected CTX reductions) in patients with T2DM, suggesting preserved bone effects of GIP in these patients. Précis Short-term GIP infusions reduce the bone resorption marker CTX by one-third in patients with type 2 diabetes independent of glycemic levels.


Sign in / Sign up

Export Citation Format

Share Document